Regulation of cellular and molecular markers of epithelial-mesenchymal transition by Brazilin in breast cancer cells.
Lorena Cayetano-SalazarJose A Hernandez-MorenoJorge Bello-MartinezMonserrat Olea-FloresEduardo Castañeda-SaucedoMonica RamirezMiguel Angel Mendoza-CatalánNapoleón Navarro-TitoPublished in: PeerJ (2024)
Breast cancer is the most common invasive neoplasm and the leading cause of cancer death in women worldwide. The main cause of mortality in cancer patients is invasion and metastasis, where the epithelial-mesenchymal transition (EMT) is a crucial player in these processes. Pharmacological therapy has plants as its primary source, including isoflavonoids. Brazilin is an isoflavonoid isolated from Haematoxilum brasiletto that has shown antiproliferative activity in several cancer cell lines. In this study, we evaluated the effect of Brazilin on canonical markers of EMT such as E-cadherin, vimentin, Twist, and matrix metalloproteases (MMPs). By Western blot, we evaluated E-cadherin, vimentin, and Twist expression and the subcellular localization by immunofluorescence. Using gelatin zymography, we determined the levels of secretion of MMPs. We used Transwell chambers coated with matrigel to determine the in vitro invasion of breast cancer cells treated with Brazilin. Interestingly, our results show that Brazilin increases 50% in E-cadherin expression and decreases 50% in vimentin and Twist expression, MMPs, and cell invasion in triple-negative breast cancer (TNBC) MDA-MB-231 and to a lesser extend in MCF7 ER+ breast cancer cells. Together, these findings position Brazilin as a new molecule with great potential for use as complementary or alternative treatment in breast cancer therapy in the future.
Keyphrases
- breast cancer cells
- epithelial mesenchymal transition
- poor prognosis
- transforming growth factor
- signaling pathway
- cancer therapy
- papillary thyroid
- squamous cell
- binding protein
- risk assessment
- south africa
- cell migration
- risk factors
- squamous cell carcinoma
- childhood cancer
- stem cells
- polycystic ovary syndrome
- young adults
- mesenchymal stem cells
- combination therapy
- pi k akt
- type diabetes
- cell therapy
- newly diagnosed
- human health